Mercury News - The (new) variants look a lot like the virus that was the template of our new bivalent booster, so vaccination still works. “It’s not a perfect match … but it’s close,” said Jeremy Kamil, a virologist at LSUHS, who studies variant mutations. “In most cases, that’s going to keep the infection in check.”
News from the Center for Emerging Viral Threats
Bloomberg - Jeremy Kamil, virologist and professor of microbiology and immunology at LSUHS, shares, "Vaccinated and previously infected people have robust and still-intact lines of defense, such as memory T-cells and B-cells. People previously infected also have additional immune cells that reside in the respiratory tract."
Nature.com - Jeremy Kamil, a virologist at Louisiana State University Health Shreveport shared, “The world needs to see more collaborations like this. Speed is crucial when it comes to fighting the virus.”
318 Forum - The 155,000-square-foot Center for Medical Education will be home to large classroom spaces, clinical skills labs and simulation suites – each designed to encourage collaboration, active engagement and innovative thinking.
Medscape - Dr. Jeremy Kamil, Associate Professor of Microbiology and Immunology at LSUHS talks with Medscape about the importance of virology in addressing concerns over hot topic viruses.
The Louisiana Board of Regents has supported full five-year approval for the Louisiana Addiction Research Center (LARC) and Center for Emerging Viral Threats (CEVT), with the CEVT continuing to be a designated Center of Research Excellence. The Board of Regents approval follows unanimous approval of both centers by the LSU Board of Supervisors earlier this year. Both centers were previously granted provisional approval and applied for full center approval earlier this year.
The Center of Excellence for Emerging Viral Threats’ (CEVT) Viral Genomics and Surveillance Lab has surpassed uploading its’ 15,000th sequence to GISAID (Global Initiative on Sharing Influenza Data). The LSU Health Shreveport CEVT team has worked tirelessly since early in the COVID-19 pandemic to sequence and track variants of SAR-CoV-2, the virus that causes the COVID-19 disease.
NY Times - Opinion - Dr. Jeremy Kamil, ... , shares "As a virologist, it’s important to me that people understand Covid-19 remains a great concern. But this does not excuse or license a misdiagnosis of the current situation."
Popular Science - The BA.5 wave may not overwhelm hospitals to the degree seen last winter, although emergency rooms and ICUs are already stretched thin. “But there’s definitely going to be an increase to some degree,” says Dr. Jeremy Kamil, a virologist who has led sequencing at LSUHS.
Louisiana Senator Bill Cassidy was instrumental in the receipt of this funding for LSUHS, which will enhance the impact of the Center for Emerging Viral Threats (CEVT) as it is able to expand significantly in the new Center for Medical Education building. Additional medical education and research opportunities will yield enhanced economic impact to the region and the state.
NBC News - Scientists have detected a handful of cases of the delta-omicron hybrid but say it's unlikely to cause a new surge. Dr. Jeremy Kamil, an associate professor of microbiology and immunology at LSUHS says, "Delta basically grabbed omicron's spike protein. This is essentially delta trying to hang on by plagiarizing from omicron."
NPR Red River Radio - Health Matters: Andrew Yurochko, PhD and Krista Queen, PhD talk about COVID Sequencing – why it matters and how LSU Health Shreveport is contributing to this international conversation.
Bloomberg - “No tests can tell you for sure what variant you have without full viral genome sequencing,” says Jeremy Kamil, a microbiologist and immunologist at LSU Health Shreveport. In the U.S., current federal guidance prevents labs from informing patients or their physicians about the specific genome-sequencing results.
New York Times - “Expect the next variant to come out of left field,” said Jeremy Kamil, a virologist at LSU Health Shreveport. He added, “It’d be a hugely foolish thing for anyone to speak with excessive certainty about what’s coming in the next two years.”
Nature - "Delta has a mutation in the spike gene that reduces some primers’ ability to bind to it, making it harder to sequence this region of the genome. Omicron doesn’t share this mutation, so if any Omicron particles were mixed into the sample owing to contamination, it might make the sequenced spike gene seem to be similar to that in Omicron," says Jeremy Kamil, a virologist at LSUHS.